Related Experiment Videos
Phase I antibody risks, trial safety examined
Journal of the National Cancer Institute
|July 20, 2006
Summary
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Plasma insulin-like growth Factor-Binding protein 7 predicts 20-Year Cancer-Specific and overall survival in ARIC.
Journal of the National Cancer Institute·2026
A taxonomy of work-related outcomes in cancer survivors to advance systematic assessments in research and practice.
Journal of the National Cancer Institute·2026
Recent trends in Early-Onset cancer incidence rates.
Journal of the National Cancer Institute·2026
Recurrence Score® gene group components and outcomes in the RxPONDER trial (SWOG S1007).
Journal of the National Cancer Institute·2026
Prevalence of industry ties in the US cancer ecosystem: a systematic review and meta-analysis.
Journal of the National Cancer Institute·2026
Mortality after emergency presentation: evidence from a cohort of 929 378 Medicare beneficiaries with common cancers diagnosed 2008-2017.
Journal of the National Cancer Institute·2026
Dabrafenib-Induced Cutaneous Eruptions in a Patient With Langerhans Cell Histiocytosis.
Case reports in dermatological medicine·2026
Type 1 diabetes mellitus induced by sintilimab: a case report and related case literature analysis.
Frontiers in endocrinology·2026
Lipocalin-2 Emerges as a Core Pathogenic Mediator and Biomarker in Autosomal Dominant Tubulointerstitial Kidney Disease-UMOD via Transcriptomic Profiling.
Kidney diseases (Basel, Switzerland)·2026
Targeting TKT-associated immunometabolic remodeling attenuates experimental lupus nephritis and NET-related inflammation.
Frontiers in cell and developmental biology·2026